Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer
Status:
Completed
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using
anastrozole or fulvestrant may fight breast cancer by lowering the amount of estrogen the
body makes or by blocking the use of estrogen by the tumor cells. Giving hormone therapy
before surgery may be an effective treatment for breast cancer. It is not yet known whether
anastrozole is more effective than fulvestrant when given before surgery in treating women
with breast cancer.
PURPOSE: This randomized phase II trial is studying anastrozole to see how well it works
compared with fulvestrant in treating postmenopausal women with stage II or stage III breast
cancer that can be removed by surgery.